Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.61 |
| ▸ | TACR3 | P29371 | 2/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | FPR1 | P21462 | 1/20 | 0.61 |
| ▸ | GPR183 | P32249 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.61 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.61 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20826783 | 0.90 | TACR1 (0.73) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Meglumine SCHEMBL4915889 | 0.83 | TACR1 (0.61) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL11929279 | 0.80 | TACR1 (0.80) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL18388496 | 0.80 | TACR1 (0.79) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL10281461 | 0.79 | TACR1 (0.78) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL18211935 | 0.79 | TACR1 (0.78) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL19853059 | 0.79 | TACR1 (0.74) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL20369072 | 0.78 | TACR1 (0.76) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL21009635 | 0.78 | TACR1 (0.73) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL12903477 | 0.78 | TACR1 (0.73) | TACR1TACR3NR3C1CYP3A4FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008400-A1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | INCOZEN THERAPEUTICS PVT LTD (IN) | 2022-01-13 | — | — | US | disclosed |
| EP-3763366-A1 | ROFLUMILAST N-OXIDE FOR USE IN TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION | Incozen Therapeutics Pvt. Ltd. (IN) | 2021-01-13 | — | — | EP | disclosed |
| EP-2948148-B1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | INCOZEN THERAPEUTICS PVT LTD (IN) | 2020-07-29 | — | — | EP | disclosed |
| US-10456390-B2 | Combinations comprising MABA compounds and corticosteroids | ALMIRALL, S.A. (ES) | 2019-10-29 | — | — | US | disclosed |
| EP-3024459-B1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ALMIRALL SA (ES) | 2019-03-27 | — | — | EP | disclosed |
| US-20180200234-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ALMIRALL, S.A. (ES) | 2018-07-19 | — | — | US | disclosed |
| US-20170196843-A1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | INCOZEN THERAPEUTICS PVT LTD (IN) | 2017-07-13 | — | — | US | disclosed |
| US-9649302-B2 | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-05-16 | — | — | US | disclosed |
| US-20160175295-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ALMIRALL, S.A. (ES) | 2016-06-23 | — | — | US | disclosed |
| EP-3024459-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | Almirall S.A. (ES) | 2016-06-01 | — | — | EP | disclosed |
| EP-1761279-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2007-03-14 | — | — | EP | disclosed |
| US-20060189651-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
| US-20060154934-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-07-13 | — | — | US | disclosed |
| US-20050288266-A1 | Combinations comprising antimuscarinic agents and corticosteroids | GRAS ESCARDO JORDI | 2005-12-29 | — | — | US | disclosed |
| WO-2005115467-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115462-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115465-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115463-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267135-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | ESCARDO JORDI G | 2005-12-01 | — | — | US | disclosed |
| US-20050267078-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | GRAS ESCARDO JORDI | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008400-A1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | NOS3, NOS2, NOS1 | TACR1 1131/4885TACR3 1848/4885NR3C1 885/4885 |
| US-20060189651-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | ADRB2, ADRB3, CHRM3 | TACR1 72/4885TACR3 117/4885NR3C1 282/4885 |
| US-20180200234-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ADRB2, ADRB3, CHRM3 | TACR1 72/4885TACR3 117/4885NR3C1 282/4885 |
| US-20050267135-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | CHRM3, PDE4A, CHRM4 | TACR1 141/4885TACR3 213/4885NR3C1 591/4885 |
| US-20050267078-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | ADRB2, ADRB3, CHRM3 | TACR1 72/4885TACR3 117/4885NR3C1 282/4885 |
| US-20160175295-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ADRB2, ADRA2A, ADRA2B | TACR1 810/4885TACR3 641/4885NR3C1 15/4885 |
| US-20170196843-A1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | NOS3, NOS2, NOS1 | TACR1 1131/4885TACR3 1848/4885NR3C1 885/4885 |
| US-20060154934-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | CHRM3, PDE4A, CHRM4 | TACR1 141/4885TACR3 213/4885NR3C1 591/4885 |
| US-20050288266-A1 | Combinations comprising antimuscarinic agents and corticosteroids | CHRM3, CHRM2, CHRM1 | TACR1 67/4885TACR3 153/4885NR3C1 18/4885 |
| US-10456390-B2 | Combinations comprising MABA compounds and corticosteroids | ADRB2, ADRA2A, ADRA2B | TACR1 810/4885TACR3 641/4885NR3C1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.